Two Sigma Securities’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $262K | Buy |
+587
| New | +$274K | 0.03% | 867 |
|
|
2025
Q3 | – | Sell |
-5,141
| Closed | -$2.29M | – | 2043 |
|
|
2025
Q2 | $2.29M | Buy |
5,141
+3,848
| +298% | +$1.77M | 0.28% | 66 |
|
|
2025
Q1 | $627K | Buy |
+1,293
| New | +$603K | 0.1% | 275 |
|
|
2024
Q4 | – | Sell |
-4,205
| Closed | -$1.96M | – | 3282 |
|
|
2024
Q3 | $1.96M | Sell |
4,205
-1,016
| -19% | -$488K | 0.03% | 551 |
|
|
2024
Q2 | $2.45M | Buy |
5,221
+1,269
| +32% | +$551K | 0.03% | 626 |
|
|
2024
Q1 | $1.65M | Sell |
3,952
-31,956
| -89% | -$13.5M | 0.02% | 862 |
|
|
2023
Q4 | $14.6M | Buy |
35,908
+29,973
| +505% | +$11.1M | 0.14% | 152 |
|
|
2023
Q3 | $2.06M | Buy |
5,935
+4,647
| +361% | +$1.63M | 0.02% | 675 |
|
|
2023
Q2 | $453K | Buy |
+1,288
| New | +$434K | 0.01% | 1502 |
|
|
2023
Q1 | – | Sell |
-903
| Closed | -$271K | – | 3320 |
|
|
2022
Q4 | $261K | Buy |
+903
| New | +$275K | 0.01% | 1676 |
|
|
2022
Q3 | – | Sell |
-1,309
| Closed | -$377K | – | 3146 |
|
|
2022
Q2 | $369K | Sell |
1,309
-22,994
| -95% | -$6.15M | 0.01% | 1130 |
|
|
2022
Q1 | $6.34M | Buy |
24,303
+18,557
| +323% | +$4.4M | 0.22% | 92 |
|
|
2021
Q4 | $1.26M | Buy |
5,746
+4,455
| +345% | +$866K | 0.05% | 211 |
|
|
2021
Q3 | $234K | Buy |
+1,291
| New | +$252K | 0.01% | 1153 |
|
|
2021
Q2 | – | Sell |
-1,529
| Closed | -$320K | – | 1738 |
|
|
2021
Q1 | $329K | Sell |
1,529
-1,299
| -46% | -$285K | 0.02% | 406 |
|
|
2020
Q4 | $668K | Buy |
2,828
+1,865
| +194% | +$428K | 0.02% | 558 |
|
|
2020
Q3 | $262K | Sell |
963
-638
| -40% | -$176K | 0.01% | 945 |
|
|
2020
Q2 | $465K | Buy |
+1,601
| New | +$434K | 0.01% | 658 |
|
|
2020
Q1 | – | Sell |
-1,093
| Closed | -$251K | – | 2378 |
|
|
2019
Q4 | $239K | Buy |
+1,093
| New | +$221K | ﹤0.01% | 1960 |
|
|
2019
Q3 | – | Sell |
-2,864
| Closed | -$507K | – | 2492 |
|
|
2019
Q2 | $525K | Buy |
+2,864
| New | +$501K | 0.01% | 1092 |
|
|
2019
Q1 | – | Sell |
-1,590
| Closed | -$294K | – | 2498 |
|
|
2018
Q4 | $263K | Sell |
1,590
-8,769
| -85% | -$1.52M | ﹤0.01% | 1498 |
|
|
2018
Q3 | $2M | Sell |
10,359
-5,297
| -34% | -$943K | 0.01% | 717 |
|
|
2018
Q2 | $2.66M | Buy |
+15,656
| New | +$2.43M | 0.01% | 753 |
|
|
2017
Q3 | – | Sell |
-2,431
| Closed | -$313K | – | 1242 |
|
|
2017
Q2 | $313K | Buy |
+2,431
| New | +$293K | 0.06% | 344 |
|
|
2017
Q1 | – | Sell |
-6,600
| Closed | -$486K | – | 1136 |
|
|
2016
Q4 | $486K | Sell |
6,600
-2,580
| -28% | -$210K | 0.16% | 151 |
|
|
2016
Q3 | $801K | Buy |
+9,180
| New | +$868K | 0.27% | 83 |
|
|
2016
Q2 | – | Sell |
-6,999
| Closed | -$556K | – | 527 |
|
|
2016
Q1 | $556K | Buy |
+6,999
| New | +$633K | 0.71% | 20 |
|
Other funds holding VRTX
VCM
VPM
Two Sigma Securities's VRTX Position: Q1 2026 in Review
Two Sigma Securities opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2026: 587 shares worth $262K. The stake represents 0.03% of the portfolio and ranks #867 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in VRTX as recently as Q2 2025.
Two Sigma Securities first reported a position in VRTX in Q1 2016 and has held it in 27 quarters since. The position peaked at $14.6M in Q4 2023. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Two Sigma Securities held 587 shares of Vertex Pharmaceuticals worth $262K as of Q1 2026.
- Vertex Pharmaceuticals was a new Two Sigma Securities position in Q1 2026.
- Vertex Pharmaceuticals made up 0.03% of Two Sigma Securities's portfolio in Q1 2026, its #867 holding.
- Two Sigma Securities first reported a position in Vertex Pharmaceuticals in Q1 2016 and has held it in 27 quarters since.
- Two Sigma Securities's Vertex Pharmaceuticals position peaked at $14.6M in Q4 2023.
- 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.